Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2020.04.11

AAALAC full accreditation

AAALAC International renews full accreditation to Sai Life Sciences for its laboratory animal care and use program

As a validation of our commitment to maintaining the highest standards in animal care and compliance with industry and regulatory guidelines, the Sai Life Sciences discovery facility in Pune recently received a renewed accreditation for its laboratory animal care and use program from AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care) International.

The Council commended the Sai Life Sciences team for providing and maintaining an excellent program of laboratory animal care and use, specifically citing its well-planned, organized and clean facility, comprehensive documentation and organized record-keeping practices.

Sai Life Sciences was first awarded the AAALAC International accreditation in February 2011 and has been accredited ever since. The present renewal is for a further period of three years up to March 2023.

“We are delighted that AAALAC has granted us the extension of full accreditation. This endorsement is a validation of our abilities to accelerate the delivery of tomorrow's medicines for our clients.” said Dr. Sarma Bugga, Senior Vice President, Discovery Services at Sai Life Sciences.

AAALAC International is a private, non-profit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Over 1,000 companies, universities, hospitals, government agencies, and other research institutions in 49 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use.

Share article

More News

2025.09.05

Reviving Kudikunta Lake: Bringing nature and community closer together

As part of its Corporate Social Responsibility initiative, Sai Life Sciences has taken up the development of Kudikunta Lake in Hyderabad, reinforcing its commitment to sustainability and community well-being. The Kudikunta Lake initiative marks a significant step in restoring one of Hyderabad’s key lakes and advancing the cause of sustainable urban living. The company has […]
Read more

2025.09.05

From injections to pills: oral peptides set to transform drug development

In a recent article published in Drug Target Review, Dr Santosh Kulkarni highlights the shift from injections to pills. He writes about how oral peptide therapeutics are overcoming the long-standing challenge of poor bioavailability—bringing us closer to patient-friendly medicines without compromising efficacy. The article highlights the booming peptide drug market and the scientific advances—from chemical […]
Read more

2025.08.28

Sai Life Sciences completes Phase II of Production Block 11 at Bidar site, India, expands capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL, was inaugurated […]
Read more

2025.08.20

Sai Life Sciences secures SBTi validation for near-term climate targets

Sai Life Sciences Limited, an innovator focused Contract Research, Development, and Manufacturing Organization (CRDMO), announced that its near-term targets to cut greenhouse gas (GHG) emissions have been validated by the Science Based Targets initiative (SBTi)—a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis. […]
Read more

2025.08.20

Sai Life Sciences featured in Drug Discovery & Development on trends shaping drug discovery

Sai Life Sciences was recently featured in Drug Discovery & Development, where Dr Maneesh Pingle, Executive Vice President and Head of Discovery Services, shared insights on the emerging trends in pharma sector. A key focus was the impact of GLP 1 agonists in accelerating peptide drug discovery. Dr. Pingle explained how the success of these […]
Read more